Oncolytic viruses: perspectives on clinical development

摘要: Developing a live anti-cancer agent derived in most cases from human pathogens presents unique set of challenges to clinical development versus those anticipated with standard chemotherapeutics and small molecules. The selection therapeutic targets for oncolytic virus (OV) development, as is true the any cancer therapy, requires careful consideration beyond preclinical early data, especially when multiple indications may initially appear equally promising. Further, added complexity potential infectious complications following OV therapy must be order efficiently safely conduct studies. As more enter clinic, these issues will become increasingly important successful drug development.